comparemela.com

Latest Breaking News On - Gina capiaux - Page 1 : comparemela.com

Sapience receives orphan designation for ST101 to treat melanoma

Sapience Therapeutics has received ODD from the US FDA for its lead programme, ST101, to treat advanced melanoma for patients in stages IIB through IV.

Barry kappelGina capiauxSapience therapeutics regulatory affairsTherapeutics regulatory affairsOrphan drug designation

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST101 for the Treatment of Advanced Melanoma

/PRNewswire/ Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address.

United statesBarry kappelAmy conradGina capiauxRegulatory affairsEuropean commissionDrug administrationPrnewswire sapience therapeutics incSapience therapeutics incOrphan drug designationVice presidentDrug designationFast track designationFast trackSapience therapeuticsChief executive

Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for Advanced Cutaneous Melanoma

/PRNewswire/ Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address.

Barry kappelAmy conradGina capiauxSapience head of regulatory affairsEuropean commissionDrug administrationSapience therapeutics incSapience therapeuticsFast track designationRegulatory affairsFast trackOrphan drug designationChief executiveInvestor contactHealth care amp hospitalsMedical pharmaceuticals

vimarsana © 2020. All Rights Reserved.